HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings,
today announced the appointment of Jill
Broadfoot to the company's Board of Directors.
Ms. Broadfoot currently serves as the Chief Financial Officer
(CFO) of aTyr Pharma, Inc., a position she has held since
July 2018. Prior to joining aTyr, Ms.
Broadfoot served as CFO of Emerald Health Pharmaceuticals and
Emerald Health Bioceuticals, where she was responsible for
establishing operations for the U.S.-based pharmaceutical and
bioceutical entities as well as the establishment of operations,
corporate governance, finance and accounting and investor relations
functions. Prior to Emerald Health, Ms. Broadfoot served as Vice
President, U.S. Corporate Controller at GW Pharmaceuticals. While
at GW Pharmaceuticals, her responsibilities included establishing
U.S. commercial operations and implementing U.S. public company
financial and accounting standards in connection with the transfer
of corporate operations from the U.K. to the U.S. Prior to joining
GW Pharmaceuticals, Ms. Broadfoot served as CFO of Vical, held
various positions at DJO Global, including as Vice President of
Finance, and served as an audit manager at Ernst & Young LLP.
Ms. Broadfoot is a member of the board of directors of Otonomy,
Inc., a publicly traded biopharmaceutical company. Ms. Broadfoot
holds a B.S. in business administration and accounting from
San Diego State University and is a
Certified Public Accountant.
"We are delighted to welcome Jill to the AcelRx Board at this
time of strategic evolution," said Vince
Angotti, AcelRx Chief Executive Officer. "Jill's experience
in finance, operations and business development come at an ideal
time for AcelRx given our ongoing corporate development and
licensing activities," continued Angotti.
"I'm thrilled to be able to support AcelRx with its planned
growth," said Jill Broadfoot. "I
believe the company is well positioned and has a solid foundation
to deliver on its ambitious objectives."
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S.,
DSUVIA® (sufentanil sublingual tablet, 30 mcg),
known as DZUVEO® in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
several product candidates. The product candidates include
Zalviso® (sufentanil sublingual tablet system, SST
system, 15 mcg), an investigational product in the U.S. being
developed as an innovatively designed patient-controlled analgesia
(PCA) system for reduction of moderate-to-severe acute pain in
medically supervised settings, and two pre-filled, ready-to-use
syringes of ephedrine and phenylephrine licensed for the U.S. from
Aguettant. DZUVEO and Zalviso are both approved products in
Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-the-appointment-of-jill-broadfoot-to-its-board-of-directors-301431235.html
SOURCE AcelRx Pharmaceuticals, Inc.